X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ASTRAZENECA PHARMA NATCO PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 16.5 160.8 10.3% View Chart
P/BV x 17.8 25.0 71.3% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ASTRAZENECA PHARMA
Mar-14
NATCO PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs8771,285 68.2%   
Low Rs424634 66.8%   
Sales per share (Unadj.) Rs223.4189.6 117.9%  
Earnings per share (Unadj.) Rs31.1-0.2 -15,259.1%  
Cash flow per share (Unadj.) Rs40.33.8 1,047.6%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.568.6 319.8%  
Shares outstanding (eoy) m33.0725.00 132.3%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.95.1 57.5%   
Avg P/E ratio x20.9-4,712.7 -0.4%  
P/CF ratio (eoy) x16.1249.6 6.5%  
Price / Book Value ratio x3.014.0 21.2%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50423,988 89.6%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m1,1281,605 70.3%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m7,3894,740 155.9%  
Other income Rs m16792 181.4%   
Total revenues Rs m7,5564,832 156.4%   
Gross profit Rs m1,793-130 -1,381.6%  
Depreciation Rs m304101 300.8%   
Interest Rs m3660-   
Profit before tax Rs m1,290-139 -928.6%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m3095 6,064.8%   
Profit after tax Rs m1,027-5 -20,184.7%  
Gross profit margin %24.3-2.7 -886.2%  
Effective tax rate %23.9-3.7 -653.1%   
Net profit margin %13.9-0.1 -12,947.7%  
BALANCE SHEET DATA
Current assets Rs m3,6812,726 135.0%   
Current liabilities Rs m3,1232,435 128.2%   
Net working cap to sales %7.66.1 123.0%  
Current ratio x1.21.1 105.3%  
Inventory Days Days8974 121.3%  
Debtors Days Days5941 144.0%  
Net fixed assets Rs m7,6851,035 742.3%   
Share capital Rs m33150 661.4%   
"Free" reserves Rs m6,670942 707.7%   
Net worth Rs m7,2591,716 423.0%   
Long term debt Rs m9550-   
Total assets Rs m11,9574,156 287.7%  
Interest coverage x4.5NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.1 54.2%   
Return on assets %11.7-0.1 -9,516.3%  
Return on equity %14.2-0.3 -4,771.7%  
Return on capital %20.70-  
Exports to sales %39.45.7 690.3%   
Imports to sales %5.76.5 88.2%   
Exports (fob) Rs m2,908270 1,076.2%   
Imports (cif) Rs m421306 137.5%   
Fx inflow Rs m3,445375 919.8%   
Fx outflow Rs m703470 149.5%   
Net fx Rs m2,743-96 -2,870.3%   
CASH FLOW
From Operations Rs m1,440-8 -17,781.5%  
From Investments Rs m-1,089-146 747.6%  
From Financial Activity Rs m-353862 -40.9%  
Net Cashflow Rs m-1709 -0.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 0.3 2,613.3%  
FIIs % 16.6 15.7 105.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 9.1 285.7%  
Shareholders   25,395 12,856 197.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PLETHICO PHARMA  DR. REDDYS LAB  GSK PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 19, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS